William Blair started coverage on shares of Loxo Oncology (NASDAQ:LOXO) in a research note published on Tuesday, Marketbeat.com reports. The brokerage issued an outperform rating on the biopharmaceutical company’s stock. William Blair also issued estimates for Loxo Oncology’s Q4 2017 earnings at ($1.16) EPS, FY2017 earnings at ($5.82) EPS, Q1 2018 earnings at ($1.17) EPS, Q2 2018 earnings at ($1.20) EPS, Q3 2018 earnings at ($1.18) EPS, Q4 2018 earnings at ($1.12) EPS, FY2018 earnings at ($4.67) EPS, FY2019 earnings at ($3.99) EPS and FY2020 earnings at ($3.16) EPS.

Several other brokerages also recently commented on LOXO. BidaskClub downgraded shares of Loxo Oncology from a hold rating to a sell rating in a research report on Friday, August 4th. JMP Securities downgraded shares of Loxo Oncology from an outperform rating to a market perform rating and cut their price objective for the company from $83.12 to $17.14 in a research report on Tuesday, August 29th. They noted that the move was a valuation call. Cowen reissued a buy rating on shares of Loxo Oncology in a research report on Thursday, September 28th. Ifs Securities raised shares of Loxo Oncology from an outperform rating to a strong-buy rating in a research report on Tuesday, November 14th. Finally, BTIG Research reissued a buy rating and set a $102.00 price objective (up from $75.00) on shares of Loxo Oncology in a research report on Friday, September 29th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $90.57.

Shares of Loxo Oncology (NASDAQ LOXO) opened at $76.87 on Tuesday. Loxo Oncology has a 1 year low of $25.25 and a 1 year high of $95.92.

In other Loxo Oncology news, Director Avi Z. Naider sold 5,000 shares of the company’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $90.00, for a total transaction of $450,000.00. Following the transaction, the director now owns 154,118 shares in the company, valued at approximately $13,870,620. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Jennifer Burstein sold 1,700 shares of the company’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $89.10, for a total transaction of $151,470.00. Following the transaction, the vice president now owns 1,700 shares in the company, valued at approximately $151,470. The disclosure for this sale can be found here. Insiders have sold a total of 1,123,596 shares of company stock worth $84,872,356 in the last 90 days. Company insiders own 44.40% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of LOXO. Teachers Advisors LLC lifted its stake in shares of Loxo Oncology by 27.2% in the 1st quarter. Teachers Advisors LLC now owns 28,162 shares of the biopharmaceutical company’s stock worth $1,185,000 after purchasing an additional 6,023 shares during the period. TIAA CREF Investment Management LLC lifted its stake in shares of Loxo Oncology by 9.7% in the 1st quarter. TIAA CREF Investment Management LLC now owns 40,772 shares of the biopharmaceutical company’s stock worth $1,716,000 after purchasing an additional 3,614 shares during the period. Legal & General Group Plc lifted its stake in shares of Loxo Oncology by 8.4% in the 1st quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 284 shares during the period. Vanguard Group Inc. lifted its stake in shares of Loxo Oncology by 42.8% in the 1st quarter. Vanguard Group Inc. now owns 733,248 shares of the biopharmaceutical company’s stock worth $30,856,000 after purchasing an additional 219,837 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Loxo Oncology by 48.0% in the 1st quarter. Geode Capital Management LLC now owns 136,276 shares of the biopharmaceutical company’s stock worth $5,734,000 after purchasing an additional 44,193 shares during the period.

ILLEGAL ACTIVITY NOTICE: “Loxo Oncology (LOXO) Now Covered by William Blair” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/12/02/loxo-oncology-loxo-now-covered-by-william-blair.html.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Analyst Recommendations for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.